Access to Direct-Acting Antiviral Treatment for Hepatitis C Virus Among Veterans With Serious Mental Illness

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.

Download Full-text

Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus

Clinical Journal of Gastroenterology ◽

10.1007/s12328-018-0922-9 ◽

2018 ◽

Vol 12 (3) ◽

pp. 213-217

Author(s):

Masako Okada ◽

Hoang Hai ◽

Akihiro Tamori ◽

Sawako Uchida-Kobayashi ◽

Masaru Enomoto ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Treatment ◽

Recombinant Hepatitis ◽

Direct Acting Antiviral ◽

Genotype 2 ◽

Direct Acting

Download Full-text

Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures

Journal of Viral Hepatitis ◽

10.1111/jvh.12932 ◽

2018 ◽

Vol 25 (11) ◽

pp. 1251-1259 ◽

Cited By ~ 5

Author(s):

Y. Jeong ◽

B. Jin ◽

H. W. Lee ◽

H. J. Park ◽

J. Y. Park ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Treatment ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Hepatology ◽

10.1002/hep.29671 ◽

2018 ◽

Vol 67 (4) ◽

pp. 1253-1260 ◽

Cited By ~ 80

Author(s):

Fred Poordad ◽

Stanislas Pol ◽

Armen Asatryan ◽

Maria Buti ◽

David Shaw ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Failure ◽

Antiviral Treatment ◽

Genotype 1 ◽

Virus Genotype ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Direct-acting antiviral therapy improves kidney survival in hepatitis C virus–associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study

Clinical Kidney Journal ◽

10.1093/ckj/sfz178 ◽

2020 ◽

Author(s):

Ana Pérez de José ◽

Javier Carbayo ◽

Anna Pocurull ◽

Teresa Bada-Bosch ◽

Clara Maria Cases Corona ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Treatment ◽

Antiviral Agents ◽

Direct Acting Antiviral ◽

Primary Endpoints ◽

Kidney Involvement ◽

Before And After ◽

Mixed Cryoglobulinaemia ◽

Direct Acting

Abstract Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04–0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04–0.33); P < 0.001]. Conclusions Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.

Download Full-text